TW200501955A - Method of treatment - Google Patents

Method of treatment

Info

Publication number
TW200501955A
TW200501955A TW093106341A TW93106341A TW200501955A TW 200501955 A TW200501955 A TW 200501955A TW 093106341 A TW093106341 A TW 093106341A TW 93106341 A TW93106341 A TW 93106341A TW 200501955 A TW200501955 A TW 200501955A
Authority
TW
Taiwan
Prior art keywords
treatment
cancers
administering
disease
patient
Prior art date
Application number
TW093106341A
Other languages
English (en)
Chinese (zh)
Inventor
David Bryant Batt
Guido Bold
Sunkyu Kim
Timothy Michael Ramsey
Michael Lloyd Sabio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200501955A publication Critical patent/TW200501955A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW093106341A 2003-03-11 2004-03-10 Method of treatment TW200501955A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11

Publications (1)

Publication Number Publication Date
TW200501955A true TW200501955A (en) 2005-01-16

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093106341A TW200501955A (en) 2003-03-11 2004-03-10 Method of treatment

Country Status (22)

Country Link
EP (1) EP1603566B1 (enExample)
JP (1) JP2006519807A (enExample)
KR (1) KR20050108383A (enExample)
CN (1) CN1758910A (enExample)
AT (1) ATE421324T1 (enExample)
AU (1) AU2004218914A1 (enExample)
BR (1) BRPI0408257A (enExample)
CA (1) CA2518530A1 (enExample)
DE (1) DE602004019193D1 (enExample)
ES (1) ES2318276T3 (enExample)
HR (1) HRP20050788A2 (enExample)
IS (1) IS8064A (enExample)
MA (1) MA27724A1 (enExample)
MX (1) MXPA05009687A (enExample)
NO (1) NO20054647L (enExample)
PL (1) PL1603566T3 (enExample)
PT (1) PT1603566E (enExample)
RU (1) RU2325159C2 (enExample)
TN (1) TNSN05223A1 (enExample)
TW (1) TW200501955A (enExample)
WO (1) WO2004080464A1 (enExample)
ZA (1) ZA200506571B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004247626B8 (en) 2003-05-15 2011-05-19 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
PE20050952A1 (es) * 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
WO2006010082A1 (en) 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
US8178672B2 (en) 2004-10-19 2012-05-15 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
JP5049970B2 (ja) * 2005-07-26 2012-10-17 サノフイ Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体
US8318941B2 (en) 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009077712A (ja) * 2007-09-11 2009-04-16 F Hoffmann La Roche Ag Ｂ−Ｒａｆキナーゼ阻害剤に対する感受性についての診断試験
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
BR112012022801B8 (pt) * 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
US9056855B2 (en) * 2010-10-28 2015-06-16 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
US20210275516A1 (en) * 2018-07-02 2021-09-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
BR9912938B1 (pt) * 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
GT200000158A (es) * 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
WO2001058899A1 (en) * 2000-02-09 2001-08-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase
WO2002060392A2 (en) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EP1364212B1 (en) * 2001-03-02 2011-02-02 GPC Biotech AG Three hybrid assay system
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
HRP20050788A2 (en) 2006-12-31
EP1603566A1 (en) 2005-12-14
CA2518530A1 (en) 2004-09-23
PT1603566E (pt) 2009-04-27
ES2318276T3 (es) 2009-05-01
DE602004019193D1 (de) 2009-03-12
ATE421324T1 (de) 2009-02-15
AU2004218914A1 (en) 2004-09-23
RU2325159C2 (ru) 2008-05-27
MXPA05009687A (es) 2005-10-20
JP2006519807A (ja) 2006-08-31
TNSN05223A1 (en) 2007-06-11
IS8064A (is) 2005-10-10
MA27724A1 (fr) 2006-01-02
CN1758910A (zh) 2006-04-12
BRPI0408257A (pt) 2006-03-07
NO20054647D0 (no) 2005-10-10
WO2004080464A1 (en) 2004-09-23
RU2005131168A (ru) 2006-05-27
NO20054647L (no) 2005-12-09
EP1603566B1 (en) 2009-01-21
ZA200506571B (en) 2006-07-26
PL1603566T3 (pl) 2009-07-31
KR20050108383A (ko) 2005-11-16

Similar Documents

Publication Publication Date Title
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
TW200501955A (en) Method of treatment
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
MXPA05011296A (es) Conjugados de fosfonato inhibidores de la cinasa.
BRPI0411365A (pt) derivados de aminopiridina
TW200720249A (en) Pyrrolidine compound
NO20026242L (no) Syntesemetoder for aplidin og nye antitumorale derivater, metoder for deresfremstilling og anvendelse av disse
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
DE602004023271D1 (de) Metastin derivate und ihre verwendung
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
NO20055033L (no) Cykliske benzimidazoler
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
SE0400708D0 (sv) New compounds and use thereof
ATE314043T1 (de) Derivate von aza-spiroverbindungen zur behandlung von schmerzen
NO20054199L (no) 6-substituerte imidazopyraziner
TW200600502A (en) Novel 6-substituted benzimidazoles
MXPA04001855A (es) Derivados de sistemas de indan-1-ol c2-sustituidos, metodos para la produccion de los mismos y su uso como medicamentos.
EA200501736A1 (ru) 2-замещённые пиримидины
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
TW200504075A (en) Imidazopyridine intermediates
DE60120398D1 (de) Imidazopyridin-8-one
PL366658A1 (en) Tricyclic epoxides
TW200504044A (en) Methods for preparing derivatives of fungicidal iodochromones and intermediate compounds